A 62-year-old man had been passing small stool for 2 months. He had been diagnosed as having mantle cell lymphoma of the spleen 8 years ago, and complete remission was achieved after chemotherapy. A computed tomography (CT) scan of the abdomen, taken to evaluate the intraabdominal lymph nodes, revealed a rectal mass with perilesional lymphadenopathy, A primary rectal cancer was suspected (• " Fig. 1, 2) . Colonoscopy revealed an ulcerative rectal mass with loss of rectal glandular structure confirmed with narrow-band imaging (• " Fig. 3, 4) . Histological examination of the biopsy specimens showed numerous lymphocytic infiltrations (• " Fig. 5, 6 ), which were positive for cyclin D1 for B cells. Recurrent mantle cell lymphoma was diagnosed and the patient was treated with rituximab-based chemotherapy. A large solitary ulcerative rectal mass is a typical presentation of primary rectal cancer. Intestinal involvement of mantle cell lymphoma, in contrast, typically presents with multiple lymphomatous polyposis [1, 2] . The stomach is the favored location [2] . Rates of involvement as documented in previous endoscopy reports are: esophagus 6 %, stomach 74 %, duodenum 34 %, ileum 48 %, cecum 14 %, colon 57 %, and rectum 48 % [4] . Intestinal lesions of mantle cell lymphoma presented as multiple lesions in nearly 80 %, whereas a protruding mass was found in 18 % [2] . Narrow-band imaging of mantle cell lymphoma of the stomach has revealed loss of normal glandular structure and tree-like appearance of abnormal blood vessels [3] . The present rectal mantle lymphoma showed hypervascularity of the mucosa with loss of standard rectal glandular structure. Immunohistochemical staining provides a definite diagnosis, and infiltrates of small, atypical lymphocyte-like cells, which stain positive with pan B-cell marker, T-cell CD5, and cyclin D1, are Recurrent mantle cell lymphoma presenting as a solitary rectal mass characteristic of the disease. Typically the disease is aggressive and the median survival is 3-5 years despite aggressive chemotherapy [4] .
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